Business
Rallybio to Present at the JMP Securities 2023 Life Sciences Conference
NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the
About this update from Rallybio Corporation
[{"type":"text","content":" NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the JMP Securities 2023 Life Sciences Conference on Monday, May 15 at 2:30 p.m. ET in New York, NY.\n\n\nA live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation.\n\n\nAbout Rallybio\n\n\nRallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 complement inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.\n\n\nRallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230503005789/en/\n\nInvestor\nAmi Bavishi\nHead of Investor Relations and Communications\n475-47-RALLY (Ext. 282)\[email protected]\n\nHannah Deresiewicz\nStern Investor Relations, Inc.\n212-362-1200\[email protected]\n\nMedia\nTara DiMilia\n908-369-7168\[email protected]\n\n\nSource: Rallybio Corporation","length":4659,"tagName":"div"}]